Literature DB >> 33438095

One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation.

Karien Esterhuizen1, J Zander Lindeque1, Shayne Mason1, Francois H van der Westhuizen1, Richard J Rodenburg2, Paul de Laat2, Jan A M Smeitink2, Mirian C H Janssen2,3, Roan Louw4,5.   

Abstract

INTRODUCTION: The m.3243A > G mitochondrial DNA mutation is one of the most common mitochondrial disease-causing mutations, with a carrier rate as high as 1:400. This point mutation affects the MT-TL1 gene, ultimately affecting the oxidative phosphorylation system and the cell's energy production. Strikingly, the m.3243A > G mutation is associated with different phenotypes, including mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD) and myopathy.
OBJECTIVES: We investigated urine metabolomes of MELAS, MIDD and myopathy patients in order to identify affected metabolic pathways and possible treatment options.
METHODS: A multiplatform metabolomics approach was used to comprehensively analyze the metabolome and compare metabolic profiles of different phenotypes caused by the m.3243A > G mutation. Our analytical array consisted of NMR spectroscopy, LC-MS/MS and GC-TOF-MS.
RESULTS: The investigation revealed phenotypic specific metabolic perturbations, as well as metabolic similarities between the different phenotypes. We show that glucose metabolism is highly disturbed in the MIDD phenotype, but not in MELAS or myopathy, remodeled fatty acid oxidation is characteristic of the MELAS patients, while one-carbon metabolism is strongly modified in both MELAS and MIDD, but not in the myopathy group. Lastly we identified increased creatine in the urine of the myopathy patients, but not in MELAS or MIDD.
CONCLUSION: We conclude by giving novel insight on the phenotypes of the m.3243A > G mutation from a metabolomics point of view. Directives are also given for future investigations that could lead to better treatment options for patients suffering from this debilitating disease.

Entities:  

Keywords:  MELAS; MIDD; Metabolomics; Mitochondrial disease; Myopathy; m.3243A > G

Year:  2021        PMID: 33438095     DOI: 10.1007/s11306-020-01769-w

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  40 in total

Review 1.  Metabolomics--the link between genotypes and phenotypes.

Authors:  Oliver Fiehn
Journal:  Plant Mol Biol       Date:  2002-01       Impact factor: 4.076

Review 2.  A guide to diagnosis and treatment of Leigh syndrome.

Authors:  Fabian Baertling; Richard J Rodenburg; Jörg Schaper; Jan A Smeitink; Werner J H Koopman; Ertan Mayatepek; Eva Morava; Felix Distelmaier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-06-14       Impact factor: 10.154

Review 3.  MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.

Authors:  Ayman W El-Hattab; Adekunle M Adesina; Jeremy Jones; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2015-06-15       Impact factor: 4.797

Review 4.  Metabolomics of mitochondrial disease.

Authors:  Karien Esterhuizen; Francois H van der Westhuizen; Roan Louw
Journal:  Mitochondrion       Date:  2017-05-31       Impact factor: 4.160

Review 5.  Genetic, pathogenetic, and phenotypic implications of the mitochondrial A3243G tRNALeu(UUR) mutation.

Authors:  J Finsterer
Journal:  Acta Neurol Scand       Date:  2007-07       Impact factor: 3.209

6.  The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR.

Authors:  Randall M Chin; Xudong Fu; Melody Y Pai; Laurent Vergnes; Heejun Hwang; Gang Deng; Simon Diep; Brett Lomenick; Vijaykumar S Meli; Gabriela C Monsalve; Eileen Hu; Stephen A Whelan; Jennifer X Wang; Gwanghyun Jung; Gregory M Solis; Farbod Fazlollahi; Chitrada Kaweeteerawat; Austin Quach; Mahta Nili; Abby S Krall; Hilary A Godwin; Helena R Chang; Kym F Faull; Feng Guo; Meisheng Jiang; Sunia A Trauger; Alan Saghatelian; Daniel Braas; Heather R Christofk; Catherine F Clarke; Michael A Teitell; Michael Petrascheck; Karen Reue; Michael E Jung; Alison R Frand; Jing Huang
Journal:  Nature       Date:  2014-05-14       Impact factor: 49.962

7.  A urinary biosignature for mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS).

Authors:  Karien Esterhuizen; J Zander Lindeque; Shayne Mason; Francois H van der Westhuizen; Anu Suomalainen; Anna H Hakonen; Christopher J Carroll; Richard J Rodenburg; Paul B de Laat; Mirian C H Janssen; Jan A M Smeitink; Roan Louw
Journal:  Mitochondrion       Date:  2018-02-19       Impact factor: 4.160

8.  Mitochondrial dysfunction remodels one-carbon metabolism in human cells.

Authors:  Xiaoyan Robert Bao; Shao-En Ong; Olga Goldberger; Jun Peng; Rohit Sharma; Dawn A Thompson; Scott B Vafai; Andrew G Cox; Eizo Marutani; Fumito Ichinose; Wolfram Goessling; Aviv Regev; Steven A Carr; Clary B Clish; Vamsi K Mootha
Journal:  Elife       Date:  2016-06-16       Impact factor: 8.140

9.  Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers.

Authors:  Jana Buzkova; Joni Nikkanen; Sofia Ahola; Anna H Hakonen; Ksenia Sevastianova; Topi Hovinen; Hannele Yki-Järvinen; Kirsi H Pietiläinen; Tuula Lönnqvist; Vidya Velagapudi; Christopher J Carroll; Anu Suomalainen
Journal:  EMBO Mol Med       Date:  2018-12       Impact factor: 12.137

10.  The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway.

Authors:  Mélissa Carbonneau; Laurence M Gagné; Marie-Eve Lalonde; Marie-Anne Germain; Alena Motorina; Marie-Christine Guiot; Blandine Secco; Emma E Vincent; Anthony Tumber; Laura Hulea; Jonathan Bergeman; Udo Oppermann; Russell G Jones; Mathieu Laplante; Ivan Topisirovic; Kevin Petrecca; Marc-Étienne Huot; Frédérick A Mallette
Journal:  Nat Commun       Date:  2016-09-14       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.